European Medicines Agency. Annex I. Summary of product characteristics. Gilenya (fingolimod). 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR)_-_Product_Information/human/002202/WC500104528.pdf.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.

Article  CAS  PubMed  Google Scholar 

Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020;87(5):688–99.

Article  CAS  PubMed  Google Scholar 

Manni A, Direnzo V, Iaffaldano A, Di Lecce V, Tortorella C, Zoccolella S, et al. Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort. Brain Behav. 2017;7(10): e00804.

Article  PubMed  PubMed Central  Google Scholar 

White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget. 2016;7(17):23106–27.

Article  PubMed  PubMed Central  Google Scholar 

Herzinger T, Kleuser B, Schäfer-Korting M, Korting HC. Sphingosine-1-Phosphate Signaling and the Skin. Am J Clin Dermatol. 2007;8(6):329–36.

Article  PubMed  Google Scholar 

Hasan Ali O, Berner F, Ackermann CJ, Ring SS, Moulin A, Müller J, et al. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunology, Immunotherapy. 2021;70(2):563–8.

Article  CAS  PubMed  Google Scholar 

European Medicine Agency. New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya. 2015. Available at: https://www.ema.europa.eu/en/documents/press-release/new-recommendations-minimise-risks-rare-brain-infection-pml-type-skin-cancer-gilenya_en.pdf.

Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Karlstad Ø, Juzeniene A, et al. Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study</p&gt. Clinical Epidemiology. 2020;12:1389–401.

Article  PubMed  PubMed Central  Google Scholar 

Cordaro A, Dobbs TD, Gibson JA, Whitaker S, Whitaker IS. Skin cancer screening in organ transplant centres in the United Kingdom: a national survey. Eur J Dermatol. 2020;30(4):372–6.

Article  PubMed  Google Scholar 

Budde K, Schutz M, Glander P, Peters H, Waiser J, Liefeldt L, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant. 2006;20(Suppl 17):17–24.

Article  PubMed  Google Scholar 

Robinson CL, Guo M. Fingolimod (Gilenya) and melanoma. BMJ Case Rep. 2016;2016.

Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, et al. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS. Neurology. 2017;89(9):970–2.

Article  PubMed  Google Scholar 

Filoni A, Lospalluti L, Giudice G, Bonamonte D, Vestita M. Fingolimod and melanoma risk: is there sufficient evidence? Clin Exp Dermatol. 2017;42(4):427–8.

Article  CAS  PubMed  Google Scholar 

Haebich G, Mughal A, Tofazzal N. Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis. Clin Exp Dermatol. 2016;41(4):433–4.

Article  CAS  PubMed  Google Scholar 

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075–84.

Article  CAS  PubMed  Google Scholar 

Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.

Article  CAS  PubMed  Google Scholar 

Australian Institute of Health and Welfare. Health system expenditure on cancer and other neoplasms in Australia, 2015–16. Canberra: AIHW; 2021 [cited 2022 Dec 23]. Available from: www.aihw.gov.au/reports/cancer/health-system-expenditure-cancer-other-neoplasms/summary.

Cohen JA, Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87(5):468-75.

Kappos L, Li DK, Stuve O, Hartung HP, Freedman MS, Hemmer B, et al. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol. 2016;73(9):1089–98.

Article  PubMed  Google Scholar 

Stamatellos VP, Rigas A, Stamoula E, Lallas A, Papadopoulou A, Papazisis G. S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal. Mult Scler Relat Disord. 2022;59: 103681.

Article  CAS  PubMed  Google Scholar 

Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept. 2017;7(2):1–6.

Article  PubMed  PubMed Central  Google Scholar 

Pašić A. Wolff K, Johnson RA, Suurmond D, eds. Fitzpatrick´ s Color Atlas and Synopsis of Clinical Dermatology. New York: McGraw-Hill, 2005. One volume. Pages 1085, parts four, sections 33. ISBN 0-07-144019-4. Acta Dermatovenerologica Croatica. 2007;15(3):0.

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160.

Article  PubMed  PubMed Central  Google Scholar 

Joanna Briggs Institute Critical Appraisal Tools. 2020. Available from: https://jbi.global/critical-appraisal-tools.

Maniscalco GT, Morra VB, Florio C, Lus G, Tedeschi G, Cianfrani M, et al. Preliminary results of the FASM study, an on-going italian active pharmacovigilance project. Pharmaceuticals. 2020;13(12):1–18.

Article  Google Scholar 

Montalban X, Comi G, Antel J, O’Connor P, De Vera A, Cremer M, et al. Long-term (>7-year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology. 2012;259(1 SUPPL. 1):S69–70.

Google Scholar 

Velter C, Thomas M, Cavalcanti A, Bastien M, Chochon F, Lubetzki C, et al. Melanoma during fingolimod treatment for multiple sclerosis. Eur J Cancer. 2019;113:75–7.

Article  CAS  PubMed  Google Scholar 

Conzett KB, Kolm I, Jelcic I, Kamarachev J, Dummer R, Braun R, et al. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Arch Dermatol. 2011;147(8):991–2.

Article  PubMed  Google Scholar 

Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012;69(2):262–4.

Article  PubMed  Google Scholar 

Carbone ML, Lacal PM, Messinese S, De Giglio L, Pozzilli C, Persechino S, et al. Multiple Sclerosis Treatment and Melanoma Development. Int J Mol Sci. 2020;21(8).

Michiels Y, Bugnon O, Michiels JF, Mazellier S. Detection of a new melanoma in a patient treated with fingolimod. BMJ Case Rep. 2019;12(4).

MSBase Neuro-immunology Registry. Available from: https://www.msbase.org/.

Norgaard M, Veres K, Didden EM, Wormser D, Magyari M. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Mult Scler Relat Disord. 2019;28:81–5.

Article  CAS  PubMed  Google Scholar 

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal. 2015;21(3):294–304.

Article  PubMed  Google Scholar 

Smith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg. 2004;30(4 Pt 2):634–41.

PubMed  Google Scholar 

Yamaguchi H, Kitayama J, Takuwa N, Arikawa K, Inoki I, Takehara K, et al. Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J. 2003;374(Pt 3):715–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. [homepage on the internet] Lyon, France: International Agency for Research on Cancer; 2020 [cited 2022 Jul 20]. Available from: https://gco.iarc.fr/today.

Novartis Pharmaceuticals UK Ltd. Gilenya, INN-fingolimod Summary of Product Characteristics. Access date: 07/01/23.

Barbieri MA, Sorbara EE, Battaglia A, Cicala G, Rizzo V, Spina E, et al. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database. Front Pharmacol. 2022;13: 808370.

Article  CAS  PubMed  PubMed Central  Google Scholar